Fulcrum Therapeutics

Losmapimod failed to improve reachable workspace (RWS) in FSHD patients at week 48, leading Fulcrum to suspend its development. Despite this, Fulcrum maintains a robust cash position to advance other therapies, including pociredir for sickle cell disease.

Corvus Pharmaceuticals' CRVS shares rose 13.9% after announcing a phase III study of soquelitinib for relapsed/refractory peripheral T-cell lymphoma (PTCL). Soquelitinib, an ITK inhibitor, aims to improve progression-free survival (PFS) and overall survival. Corvus' shares have surged 163.4% YTD, contrasting the industry's 1.6% decline.